Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Selpercatinib for advanced thyroid cancer with RET alterations	Selpercatinib (LOXO-292; LY3527723)	Medullary thyroid cancer (MTC) , Thyroid cancer	Head and Neck Cancer , Oncology	2019	View \| Download
Selpercatinib for metastatic RET fusion-positive non-small cell lung cancer	Selpercatinib (LOXO-292; LY3527723)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Selumetinib for neurofibromatosis type 1	Selumetinib (AZD6244; ARRY-142886)	Neurofibromatosis	Neurology	2019	View \| Download
Setmelanotide for rare genetic obesity due to leptin receptor deficiency	Setmelanotide (RM-493)	Obesity due to Leptin receptor deficiency	Endocrine Nutritional and Metabolic Disorders	2019	View \| Download
Sotagliflozin for type 2 diabetes mellitus	Sotagliflozin (Zynquista; SAR439954; LX4211)	Type 2 diabetes	Endocrine Nutritional and Metabolic Disorders	2019	View \| Download
Spartalizumab in addition to dabrafenib and trametinib for unresectable or metastatic BRAF V600 mutant melanoma – first‐line	Dabrafenib (Tafinlar; GSK2118436; dabrafenib mesilate) , Spartalizumab (PDR001) , Trametinib (Mekinist; TMT212; GSK-1120212B; GSK1120212; JTP-74057; trametinib dimethyl sulfoxide)	Melanoma	Skin Cancer	2019	View \| Download
Tabelecleucel for Epstein-Barr Virus-associated lymphoproliferative disease following solid organ transplant	Tabelecleucel (Tab-cel; ATA129)	Post-transplant lymphoproliferative disease (PTLD)	Haematological Cancer and Lymphomas	2019	View \| Download
Tanezumab for moderate to severe chronic pain associated with osteoarthritis and chronic low back pain	Tanezumab (PF-04383119; RN624)	Back pain , Osteoarthritic pain	Musculoskeletal System , Pain Relief , Rheumatology	2019	View \| Download
Tezacaftor and ivacaftor for cystic fibrosis homozygous or heterozygous for F508del mutation in patients aged 12 years and older who discontinued treatment with Orkambi	Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download
Tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation and one residual mutation in patients aged 6 to 11 years	Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download